1700008G05Rik Inhibitors
Chemical inhibitors of the protein 1700008G05Rik can affect its function through various biochemical pathways by targeting specific kinases and enzymes that are likely involved in its regulation. Staurosporine is a broad-spectrum kinase inhibitor that can disrupt multiple signaling pathways that may converge on the regulation of 1700008G05Rik. By inhibiting general kinase activity, it can prevent the phosphorylation that would typically modulate the protein's function. Similarly, Bisindolylmaleimide I, which specifically inhibits Protein Kinase C (PKC), can suppress the function of 1700008G05Rik if PKC is part of its regulatory mechanism. LY294002 and Wortmannin, both phosphoinositide 3-kinase (PI3K) inhibitors, can obstruct the PI3K/Akt pathway, which is often central to cellular signaling related to survival and proliferation, and if 1700008G05Rik is a downstream effector in this pathway, its activity would be inhibited.
Further, PD98059 and U0126, as inhibitors of MEK, can hinder the MAPK/ERK signaling cascade; if 1700008G05Rik relies on this pathway for its activation or repression, these inhibitors can reduce its activity. The c-Jun N-terminal kinase (JNK) pathway, which can be interrupted by SP600125, is another potential regulator of 1700008G05Rik, and inhibition here would also lead to decreased protein activity. Y-27632 targets the Rho-associated protein kinase (ROCK), and if 1700008G05Rik operates downstream of ROCK, Y-27632 would result in diminished activity. SB203580, by inhibiting p38 MAP kinase, can similarly reduce the activity of 1700008G05Rik if it is part of the p38 MAPK regulatory network. Finally, PP1 and PP2 inhibit Src family tyrosine kinases, and if these kinases phosphorylate or otherwise affect 1700008G05Rik, the use of these inhibitors can lead to reduced activity of the protein. Rapamycin's inhibition of mTOR can also suppress the activity of 1700008G05Rik if it is regulated as part of the PI3K/Akt/mTOR pathway. These inhibitors collectively can modulate the activity of 1700008G05Rik through their targeted action on specific kinases and signaling pathways within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a wide range of protein kinases. Since 1700008G05Rik is a protein, it may be affected by changes in phosphorylation status due to kinase activity. Staurosporine would inhibit the kinases that phosphorylate 1700008G05Rik, leading to a decrease in its functional activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
This compound selectively inhibits Protein Kinase C (PKC). If 1700008G05Rik is activated or regulated by PKC, then inhibition by Bisindolylmaleimide I would result in a reduction of its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 would prevent downstream signaling required for the function of 1700008G05Rik, assuming that this protein is regulated by PI3K/Akt pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. It would inhibit the PI3K/Akt pathway, which could be responsible for the functional regulation of 1700008G05Rik. This would result in inhibited activity of the protein. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK/ERK pathway. By inhibiting MEK, PD98059 prevents the activation of ERK and its downstream targets. If 1700008G05Rik is regulated through this pathway, its activity would be inhibited as well. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that would inhibit ERK activation. Inhibition of the MAPK/ERK pathway would lead to a reduction in 1700008G05Rik activity, assuming that ERK signaling is involved in its regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits the c-Jun N-terminal kinase (JNK). If 1700008G05Rik activity is regulated by JNK signaling pathways, inhibition by SP600125 would lead to a decrease in the functional activity of 1700008G05Rik. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits the Rho-associated protein kinase (ROCK). If 1700008G05Rik operates downstream of ROCK, the use of Y-27632 would result in inhibited activity of 1700008G05Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. Inhibition of p38 MAPK signaling would reduce the activity of 1700008G05Rik if p38 MAPK is a part of the regulatory network for this protein. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR, which is part of the PI3K/Akt/mTOR pathway. Inhibition of mTOR would affect the functional activity of 1700008G05Rik if the protein is regulated as part of this pathway. | ||||||